Project name(s): Hyperstim (EIC Pathfinder Challenge, 2022 - 2026) and Flairvision (EIC Transition, 2025 - 2028)
Company partner: ReVision Implant
EU Contribution to Revision Implant: almost €1 500 000
Location: Belgium
Coupled with the ongoing, and to date successful, Pathfinder Challenge project (Hyperstim), ReVision Implant and partners have recently awarded EIC Transition support (via the Flairvision project), to ensure continuation of their mission to give vision back to the blind.
Vision & ImpactCurrently, there is no high-technological solution for blindness available, and blind patients have to resort to guide dogs or reading software. Our visual prosthesis will provide functional artificial vision to the blind, allowing them to regain independence and participate in social life again.
CollaborationThrough EIC, we have built a valuable network with leading experts all over Europe, both from companies and academic institutions. The support programs of EIC Access+ also allowed us to collaborate with dedicated regulatory and IP companies, further accelerating our growth as a company.
What's next ?After first-in-human tests, we will continue product development of the final visual prosthesis. This will allow us to start a feasibility clinical trial, the first step towards a commercial medical device. The company is also actively fundraising to fund these future developments.
The EIC Pathfinder and Transition grants have been invaluable to demonstrate our first proof-of-principle, to evolve from an early-stage technology company into a medical device manufacturer, and to get closer to the market.
Furthermore, the European consortium truly combines the most experienced researchers in their domains from all over Europe, which is crucial in the international competitive landscape. Lastly, the EIC support has contributed to our credibility for investors, allowing us to bridge the gap between academic funding and seed investment, to larger investments from private and institutional investors.
ReVision Implant's Timeline
- April 2022
- August 2023
First proof-of-concept of artificial vision generated with our novel electrode arrays in non-human primates
- June 2024
First version of the human-sized electrode arrays
- January 2025
- March 2025
Start of a strategic collaboration with Cochlear, the world leader in cochlear implants
- April 2025
First proof-of-concept of the active implantable stimulator, an important milestone for the future visual prosthesis
- May 2025
Received the intention to grant for our first patent about electrode technology, and continued to file other patents about core IP
- October 2025
Regulatory approval filed in Hungary to start acute first-in-human testing